We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

A higher dose of Spinraza may be more effective than the currently approved dosing schedule for maintaining motor function in ...

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...

After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with an intrathecal formulation intended for older patients.

Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a ...

Biogen Inc. ( NASDAQ: BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Great. Good morning, everybody. Happy to be moderating my annual panel where Priya has to listen to me ...

Detailed price information for Camp4 Therapeutics Corp (CAMP-Q) from The Globe and Mail including charting and trades.

Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?

Per the deal terms, IONS will receive an upfront payment of $280 million from Ono. It is also eligible for milestone payments of up to $660 million.

I got my 7th Spinraza injection and it was quite a long day!